Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up
- PMID: 12011609
- DOI: 10.1097/00005053-200205000-00005
Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up
Abstract
This study examined the effect of antidepressants in preventing depression after stroke. Nondepressed poststroke patients (N = 48) were randomly assigned to receive nortriptyline, fluoxetine, or placebo for 3 months by using double-blind methodology and were followed-up for 21 months by using a naturalistic design. During the treatment period, one minor depression developed in the nortriptyline group (n = 13 at 3 months), one minor depression developed in the fluoxetine group (n = 13), and five minor depressions developed in the placebo group (n = 15; p <.05). When treatment was discontinued, nortriptyline-treated patients were more likely to develop depression and had significantly more severe depressive symptoms during the next 6 months compared with patients in the other two groups. Both nortriptyline and fluoxetine appeared to be efficacious in preventing depression after stroke. However, nortriptyline produced an increased vulnerability to depression for more than 6 months after it was discontinued. This finding suggests the need to extend prophylactic treatment and monitor patients carefully after the discontinuation of nortriptyline.
Similar articles
-
Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.Am J Psychiatry. 2000 Mar;157(3):351-9. doi: 10.1176/appi.ajp.157.3.351. Am J Psychiatry. 2000. PMID: 10698809 Clinical Trial.
-
Poststroke depression.Am J Psychiatry. 2001 Apr;158(4):658-60. doi: 10.1176/appi.ajp.158.4.658-a. Am J Psychiatry. 2001. PMID: 11282720 No abstract available.
-
Risk factors for and correlates of poststroke depression following discontinuation of antidepressants.J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):399-405. doi: 10.1176/jnp.2007.19.4.399. J Neuropsychiatry Clin Neurosci. 2007. PMID: 18070842 Clinical Trial.
-
Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.Drugs. 2001;61(1):81-110. doi: 10.2165/00003495-200161010-00010. Drugs. 2001. PMID: 11217873 Review.
-
Fluoxetine: a suitable long-term treatment.J Clin Psychiatry. 2001;62 Suppl 22:24-9. J Clin Psychiatry. 2001. PMID: 11599644 Review.
Cited by
-
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression after stroke.Cochrane Database Syst Rev. 2020 May 11;5(5):CD003689. doi: 10.1002/14651858.CD003689.pub4. Cochrane Database Syst Rev. 2020. PMID: 32390167 Free PMC article.
-
Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2022 Jul 5;11(13):e025868. doi: 10.1161/JAHA.122.025868. Epub 2022 Jun 22. J Am Heart Assoc. 2022. PMID: 35730636 Free PMC article.
-
A Systematic Review of Loneliness and Common Chronic Physical Conditions in Adults.Open Psychol J. 2015;8(Suppl 2):113-132. doi: 10.2174/1874350101508010113. Epub 2015 May 15. Open Psychol J. 2015. PMID: 26550060 Free PMC article.
-
Gene-environment interactions in geriatric depression.Psychiatr Clin North Am. 2011 Jun;34(2):357-76, viii. doi: 10.1016/j.psc.2011.02.003. Psychiatr Clin North Am. 2011. PMID: 21536163 Free PMC article. Review.
-
Increased frequency of first-episode poststroke depression after discontinuation of escitalopram.Stroke. 2011 Nov;42(11):3281-3. doi: 10.1161/STROKEAHA.111.626507. Epub 2011 Aug 25. Stroke. 2011. PMID: 21868736 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical